Braveheart Bio Inc.
Organization details
- Legal name
- Braveheart Bio Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BRVE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002131524
- EIN
- 99-2981994
Board of directors
-
Christopher Viehbacher · DirectorSince 2026
-
David Charles Lubner · DirectorSince 2026
-
David I. Malek · DirectorSince 2026
-
Erez Chimovits · DirectorSince 2026
-
Jason Coloma V · DirectorSince 2026
-
Jasper Bos · DirectorSince 2026
-
Tim Lohoff · DirectorSince 2026
-
Travis Murdoch · Director · CEO and PresidentSince 2026
-
Vineeta Agarwala · DirectorSince 2026
Chief executives
Board connections
6 of this board's directors also sit on 10 other boards. 10 are in the same sector.
-
ADARx Pharmaceuticals Inc. Same sectorvia Erez Chimovits
-
Adicet Bio Inc. Same sectorvia Erez Chimovits
-
Biogen Inc. Same sectorvia Christopher Viehbacher
-
Crescent Biopharma Inc. Same sectorvia David Charles Lubner
-
Dyne Therapeutics Inc. Same sectorvia David Charles Lubner
-
Maze Therapeutics Inc. Same sectorvia Jason Coloma V
-
Tenet Healthcare Corporation Same sectorvia Vineeta Agarwala
-
Upstream Bio Inc. Same sectorvia Erez Chimovits
-
Vor Biopharma Inc. Same sectorvia David Charles Lubner
-
enGene Therapeutics Inc. Same sectorvia Jasper Bos
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $159,034,950
- 13 purchases by 10 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 7, 2026 | Anderson Michele A. Officer (Chief Development Officer) | Open-market purchase | +1,111 | $18.00 | $19,998 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. 10% owner | Derivative conversion | +9,132,420 | — | — |
| Aug 7, 2026 | David Charles Lubner Director | Open-market purchase | +55,555 | $18.00 | $999,990 |
| Aug 7, 2026 | Travis Murdoch Director, Officer (CEO and President) | Open-market purchase | +83,333 | $18.00 | $1,499,994 |
| Aug 7, 2026 | David I. Malek Director | Open-market purchase | +4,166 | $18.00 | $74,988 |
| Aug 7, 2026 | Christopher Viehbacher Director | Open-market purchase | +83,333 | $18.00 | $1,499,994 |
| Aug 7, 2026 | Rickey James Paul Officer (Chief Financial Officer) | Open-market purchase | +27,777 | $18.00 | $499,986 |
| Aug 7, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner | Derivative conversion | +7,420,091 | — | — |
| Aug 7, 2026 | Marc L. Andreessen 10% owner | Derivative conversion | +9,132,420 | — | — |
| Aug 7, 2026 | OrbiMed Genesis GP LLC Director, 10% owner | Derivative conversion | +9,132,420 | — | — |
| Aug 7, 2026 | Erez Chimovits Director, 10% owner | Derivative conversion | +9,132,420 | — | — |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. 10% owner | Derivative conversion | +7,990,867 | — | — |
| Aug 7, 2026 | Marc L. Andreessen 10% owner | Open-market purchase | +1,100,000 | $18.00 | $19,800,000 |
| Aug 7, 2026 | OrbiMed Genesis GP LLC Director, 10% owner | Open-market purchase | +1,666,667 | $18.00 | $30,000,006 |
| Aug 7, 2026 | Erez Chimovits Director, 10% owner | Open-market purchase | +1,666,667 | $18.00 | $30,000,006 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Braveheart Bio Inc.
Who is the CEO of Braveheart Bio Inc.?
Travis Murdoch has been Braveheart Bio Inc.'s CEO and President since August 2026.
How many directors are on Braveheart Bio Inc.'s board?
Braveheart Bio Inc.'s board has 9 directors: Christopher Viehbacher, David Charles Lubner, David I. Malek, Erez Chimovits, Jason Coloma V, Jasper Bos, Tim Lohoff, Travis Murdoch and Vineeta Agarwala.
Are Braveheart Bio Inc. insiders buying or selling shares?
Over the last 12 months, Braveheart Bio Inc. insiders bought $159.0 million of shares in 13 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="braveheart-bio-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.